Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Bosomworth

Interventional Pain Medicine Frankfort, KY Medical Doctor

NPI 1164518080 CMS profile 7181

279 Kings Daughters Dr Ste 100, Frankfort, KY 40601

Open in the dashboard

General payments

$8,723

260 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Bosomworth of Frankfort, KY is reported in the CMS Open Payments database as having received $8,723 across 260 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $386 19
2024 General $887 26
2023 General $674 30
2022 General $998 25
2021 General $1,692 51
2020 General $1,265 48
2019 General $2,822 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Bosomworth
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to David Bosomworth were reported at $386. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year David Bosomworth Interventional Pain Medicine median Middle half National median
2019 $2,822 $684 $216–$2,079 $163
2020 $1,265 $382 $122–$1,109 $114
2021 $1,692 $552 $167–$1,554 $132
2022 $998 $605 $187–$1,924 $149
2023 $674 $671 $195–$1,915 $160
2024 $887 $684 $206–$1,837 $164
2025 $386 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $2,192 20 payments
  2. Abbott Laboratories $1,150 18 payments
  3. Boston Scientific Corporation $863 23 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $623 33 payments
  5. Medtronic, Inc. $385 4 payments
  6. Collegium Pharmaceutical, Inc. $358 22 payments
  7. Saluda Medical Americas, Inc. $320 10 payments
  8. Nevro Corp. $312 15 payments
  9. Scilex Pharmaceuticals Inc. $254 17 payments
  10. Foundation Fusion Solutions, LLC $212 1 payment
  11. Other $2,054 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,687 258 payments
  2. Travel and Lodging $1,036 2 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMED $1,645 11 payments
  2. RELISTOR $529 28 payments
  3. GENERAL PAIN MANAGEMENT $443 6 payments
  4. INTELLIS ADAPTIVESTIM $374 2 payments
  5. ASCENDA $368 2 payments
  6. Proclaim IPG $350 5 payments
  7. Evoke $320 10 payments
  8. XTAMPZA $303 19 payments
  9. Neuromodulation Dspsbls and Accs $284 7 payments
  10. PROCLAIM $234 2 payments
  11. Other $4,141 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

30,808

Median for Pain Management: 951

Drug cost

$668,832

Median for Pain Management: $26,034

Branded share of claims

41.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 7,615 $139,634
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 4,613 $92,115
Relistor Methylnaltrexone Bromide Brand 34 $72,198
Gabapentin Generic 7,178 $68,857
Oxycodone Hcl Generic 2,024 $32,197
Pregabalin Generic 1,033 $29,327
Movantik Naloxegol Oxalate Brand 61 $25,206
Orphenadrine-Aspirin-Caffeine Orphenadrine/Aspirin/Caffeine Brand 16 $24,331
Linzess Linaclotide Brand 40 $21,026
Tizanidine Hcl Generic 1,821 $19,159

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$487,002

Of which drugs: $6,878

Medicare patients

596

Average age 66

Services billed

10,045

366 women, 230 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Diabetes 37%
Depression 37%
COPD 34%
Ischemic heart disease 27%
Chronic kidney disease 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 36 3,200 $915
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 48 336 $257
Injection, methylprednisolone acetate, 40 mg J1030 Office 29 39 $196
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 18 604 $54

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $218
$218 34 —
ZTLido
  • Scilex Pharmaceuticals Inc. $32
$32 39 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $20
$20 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

260 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record